not happening today Eli Lilly (NYSE:LLY) on Thursday said the U.S. Food and Drug Administration (FDA) had rejected its accelerated approval submission of its Alzheimer's treatment donanemab. Shares of the U.S. drugmaker fell 3.2% to $340 after hours. "In the complete response letter to the accelerated approval application, the FDA specifically requested that Lilly provide data from at least 100 patients who received a minimum of 12 months of continued treatment on donanemab," LLY said in a statement. The company said that its confirmatory late-stage trial for donanemab remains ongoing and that topline data was expected in Q2 2023. According to LLY, "while the trial included more than 100 patients treated with donanemab, due to the speed of plaque reduction, many patients were able to stop dosing as early as 6 months of treatment, resulting in fewer than 100 patients receiving 12 months of donanemab."